
NIFTY Pharma Prediction for Tomorrow 12 June 2026: Key Levels and Sector Outlook
NIFTY Pharma 24,306.95 (+0.60%) on 11 Jun. High 24,457.30, low 24,094.40. Cautiously Bullish. Support 24,100, resistance 24,460. SpaceX IPO 12 Jun.
Updated: 11 Jun 2026 • 4:25 pm
Posted by:

The NIFTY Pharma prediction for tomorrow 12 June 2026 is Cautiously Bullish after the index closed at 24,306.95 (+0.60%) on 11 June 2026 with an intraday high of 24,457.30 and low of 24,094.40. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. The NIFTY Pharma prediction for tomorrow is shaped by two macro variables: the confirmed US CPI (headline 4.2% YoY, core 0.2% MoM — soft below estimate) and the SpaceX Nasdaq listing on 12 June creating potential overnight US market volatility. Pre-Fed positioning ahead of June 16-17, 2026 is the dominant global theme. Ankit Jaiswal, Senior Research Analyst at Univest, and Kunal Singla, Associate Director at Univest, provide the key levels for the NIFTY Pharma prediction for tomorrow 12 June 2026.
Click Here – Get Free Investment Predictions
Market Context: 11 June 2026 Session
- Nifty 50: 23,161.60 (-0.23%). High 23,327.45, low 23,072.05 (Put OI held).
- Bank Nifty: 55,176.75 (+0.14%). New recovery high 55,600.15. ICICI Bank +1.83% (high Rs 1,333.00). Pvt Bank +0.55%.
- US CPI (May 2026): Headline 4.2% YoY (in-line). Core CPI 0.2% MoM — BELOW 0.3% estimate. Energy-driven not broad-based.
- India VIX: 15.61 (prev 15.63). Stable and slightly lower.
- Key global event tomorrow: SpaceX Nasdaq listing on 12 June; Fed meeting June 16-17, 2026.
- No expiry tomorrow: 12 June is a regular Friday session. BSE Sensex weekly expired today (Thursday 11 June).
NIFTY Pharma Technical Levels for Tomorrow 12 June 2026
| Parameter | Value |
|---|---|
| 11 June Close | 24,306.95 |
| Previous Close (10 June) | 24,160.75 |
| Change | +0.60% |
| Intraday High | 24,457.30 |
| Intraday Low | 24,094.40 |
| Support 1 | 24,100 |
| Support 2 | 23,800 |
| Resistance 1 | 24,460 |
| Resistance 2 | 24,700 |
| Trend | Cautiously Bullish |
3 Stocks Building Serious Momentum Right Now
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Top Stock Picks on Univest
NIFTY Pharma Prediction for Tomorrow: Sector Analysis
Ankit Jaiswal observes that the NIFTY Pharma prediction for tomorrow is anchored at 24,100 support. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. A break above 24,460 confirms the NIFTY Pharma prediction for tomorrow recovery case.
Kunal Singla notes that the NIFTY Pharma prediction for tomorrow is also influenced by overnight global factors: SpaceX Nasdaq listing on 12 June and Dollar Index direction. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. He recommends checking GIFT Nifty at 9:00 AM IST before any NIFTY Pharma related positions tomorrow.
Catalyst for NIFTY Pharma Prediction for Tomorrow
USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. These sector-specific catalysts combined with the US CPI (core 0.2% MoM soft) and SpaceX IPO will determine the NIFTY Pharma prediction for tomorrow 12 June 2026.
Check the Univest Screener for live NSE/BSE data
Conclusion
The NIFTY Pharma prediction for tomorrow 12 June 2026 is Cautiously Bullish with 24,100 as key support and 24,460 as resistance. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. Data sourced from open public platforms including NSE and BSE — verify from official sources before decisions.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Disclaimer: The securities quoted are for illustration purposes only and are not recommendatory. This is for educational purposes only and shall not be considered as investment advice by Univest (Uniresearch Global Pvt Ltd, SEBI Registered Research Analyst INH000013776). Investments are subject to market risks. Data is sourced from open public platforms including NSE, BSE and MCX and may be subject to revision. Always verify from official exchange sources before any investment decision. Past performance is not indicative of future results.
Frequently Asked Questions
What is the NIFTY Pharma prediction for tomorrow 12 June 2026?
Ans. The NIFTY Pharma prediction for tomorrow is Cautiously Bullish. It closed at 24,306.95 (+0.60%) on 11 June with a high of 24,457.30 and low of 24,094.40. Support is 24,100 and resistance is 24,460. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured.
What are NIFTY Pharma support and resistance for tomorrow?
Ans. Support 1: 24,100. Support 2: 23,800. Resistance 1: 24,460. Resistance 2: 24,700. A break above 24,460 confirms the bullish case for the NIFTY Pharma prediction for tomorrow.
What drives the NIFTY Pharma prediction for tomorrow?
Ans. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured. The SpaceX Nasdaq listing on 12 June and pre-Fed positioning ahead of June 16-17, 2026 are the key global variables.
How does core CPI affect NIFTY Pharma prediction for tomorrow?
Ans. Core CPI at 0.2% MoM (below 0.3% estimate) reduces Fed hike fears, supporting rate-sensitive sectors. Hot headline CPI 4.2% YoY pressures cost-sensitive sectors. The net effect on NIFTY Pharma prediction for tomorrow depends on the sector's specific sensitivity.
Is NIFTY Pharma bullish or bearish for 12 June 2026?
Ans. The NIFTY Pharma prediction for tomorrow is Cautiously Bullish. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed are the key catalysts. VIX at 15.61 and Nifty at 23,161.60 set the broad backdrop.
What is the key catalyst for NIFTY Pharma prediction for tomorrow?
Ans. USFDA drug approvals; defensive demand continuation as market remains cautious pre-Fed. Additionally, SpaceX Nasdaq listing on 12 June creates overnight volatility that will influence global risk sentiment and FII flows into all NSE sectors.
What happened to NIFTY Pharma today 11 June 2026?
Ans. NIFTY Pharma closed at 24,306.95 (+0.60%) on 11 June with high 24,457.30 and low 24,094.40. Defensive sector outperformance; institutional rotation from FMCG into pharma; Wockhardt +5.84% and Gland Pharma +4.44% led gains; mid-cap pharma exporters favoured.
What is the key risk for NIFTY Pharma prediction for tomorrow?
Ans. Primary risk: SpaceX IPO creating US market volatility and FII flow disruption. Secondary: hot headline CPI 4.2% YoY pressuring inflation-sensitive sectors. Use stop-losses at 24,100 for long positions in NIFTY Pharma tomorrow.
Download the Univest iOS App or Univest Android App to track NIFTY Pharma live price and get daily predictions.
Recent Articles

Voltas vs Dixon Technologies: Which Stock Should You Track
28 July 2026

HDFC Bank vs ICICI Bank: Which Stock Should You Track
28 July 2026

Axis Conservative Hybrid Direct Annual IDCW: NAV Today, Performance Review and Should You Invest?
27 July 2026

Axis Silver of Direct IDCW: NAV Today, Performance Review and Should You Invest?
27 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Voltas vs Dixon Technologies: Which Stock Should You Track
HDFC Bank vs ICICI Bank: Which Stock Should You Track
Axis Conservative Hybrid Direct Annual IDCW: NAV Today, Performance Review and Should You Invest?
Axis Silver of Direct IDCW: NAV Today, Performance Review and Should You Invest?
Axis Multi Asset Active FoF Direct Growth: NAV Today, Performance Review and Should You Invest?
Popular this week
Voltas vs Dixon Technologies: Which Stock Should You Track
HDFC Bank vs ICICI Bank: Which Stock Should You Track
Axis Conservative Hybrid Direct Annual IDCW: NAV Today, Performance Review and Should You Invest?
Axis Silver of Direct IDCW: NAV Today, Performance Review and Should You Invest?
Axis Multi Asset Active FoF Direct Growth: NAV Today, Performance Review and Should You Invest?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





